TP53 and non-small cell lung carcinoma: With regard to type of tumor, concurrent TP53 mutations were poor prognostic factors in patients with both ADC (Pooled HR for PFS = 1.97, 95% CI:1.61–2.41, P < 0.001, heterogeneity: I2 = 0.0%, P = 0.755; Pooled HR for OS = 1.81, 95% CI: 1.33–2.46, P < 0.001, heterogeneity: I2 = 0.0%, P = 0.435) and all NSCLC subtypes (Pooled HR for PFS = 1.70, 95% CI:1.25–2.31, P = 0.001, heterogeneity: I2 = 0.0%, P = 0.518; Pooled HR for OS = 2.03, 95% CI: 1.51–2.73, P < 0.001, heterogeneity: I2 = 0.0%, P = 0.413) (Fig. 4a,b).